Gabapentin is an effective alternative to standard pain-control drugs and can manage head and neck cancer pain and symptoms without the need for narcotics, a study published in Cancer found.
Responders who worked at the World Trade Center site after the attacks on Sept.11, 2001, have an increased overall cancer incidence, compared to the general population, particularly in thyroid cancer, prostate cancer, and, for the first time ever reported, leukemia, according to a Mount Sinai study published in JNCI Cancer Spectrum Jan. 14.
Oliver Bogler was named director of the NCI Center for Cancer Training. He will focus on NCI training and career development programs to develop cancer research through a scientifically-integrated approach.
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center has joined the Big Ten Cancer Research Consortium.
Victor J. Dzau, president of the National Academy of Medicine, has been elected to a second six-year term, beginning in July. In addition, Carlos del Rio, executive associate dean for Emory University School of Medicine at Grady Health System, has been elected as the next foreign secretary of the National Academy of Medicine.
Bert Vogelstein, Johns Hopkins Kimmel Cancer Center, Ludwig Center, Lustgarten Laboratory, and Howard Hughes Medical Institute received on Jan. 22, the prestigious 2020 Jessie Stevenson Kovalenko Medal, presented by the National Academy of Sciences to outstanding contributors in the medical sciences.
Faculty from Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, MD Anderson Cancer Center, University of Chicago, University of Pennsylvania and Florida International University are joining Miami Cancer Institute Jan. 24-25 for its inaugural Symposium on Immunotherapies for Hematologic Malignancies.
Smilow Cancer Hospital at Yale New Haven announces four appointments:
City of Hope will open its Newport Beach site on Jan. 27.
Stand Up To Cancer is announcing a health equity initiative with the goal of increasing diversity in cancer clinical trials.
